Evidence map›Paper›PMID 22316239›Full record

ReviewJournal of natural products2012

Natural products as sources of new drugs over the 30 years from 1981 to 2010.

David J Newman, Gordon M Cragg

Registry-linked trialAbstract readHistorical ArticleReview
In one paragraph

Review in Journal of natural products, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07436130 (Immunomodulatory Effect of Curcumin in Critically Ill Patients With Sepsis at the Antiguo Hospital Civil de Guadalajara "Fray Antonio Alcalde"), which is not on this map. Cited by 1,508 papers.

0numbers the graph read from it
0cells of the map it votes in
1,508citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07436130 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Immunomodulatory Effect of Curcumin in Critically Ill Patients With Sepsis at the Antiguo Hospital Civil de Guadalajara "Fray Antonio Alcalde": A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

TypeinterventionalSponsorHospital Civil de GuadalajaraRan2026 to 2027Enrolled56ConditionsSepsisArmsCurcumin, Placebo
3 · Its place in the literature

Who cites it

1,508 citing papers in PubMed.

  1. Trial
  2. Overview of Conservation of Microbial Genetic Resources.Methods in molecular biology (Clifton, N.J.) · 2027
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Tropanes in natural products, syntheses, and drugs: some insights from the new millennium.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026
    Review
  14. Article
  15. Bioactivity ofMolecules (Basel, Switzerland) · 2026
    Article
  16. Article
  17. Review
  18. Antibacterial potential of danthron, embelin, sanguinarine and shikonin against multidrug-resistant Neisseria gonorrhoeae in vitro.International microbiology : the official journal of the Spanish Society for Microbiology · 2026
    Article
  19. Article
  20. Review

1,448 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

David J NewmanNatural Products Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute-Frederick, P.O. Box B, Frederick, Maryland 21702, United States. newmand@mail.nih.gov
Gordon M Cragg

Funding

Intramural NIH HHS Z99 CA999999NCI NIH HHS Y99 CA999999
6 · The paper itself

Abstract

This review is an updated and expanded version of the three prior reviews that were published in this journal in 1997, 2003, and 2007. In the case of all approved therapeutic agents, the time frame has been extended to cover the 30 years from January 1, 1981, to December 31, 2010, for all diseases worldwide, and from 1950 (earliest so far identified) to December 2010 for all approved antitumor drugs worldwide. We have continued to utilize our secondary subdivision of a "natural product mimic" or "NM" to join the original primary divisions and have added a new designation, "natural product botanical" or "NB", to cover those botanical "defined mixtures" that have now been recognized as drug entities by the FDA and similar organizations. From the data presented, the utility of natural products as sources of novel structures, but not necessarily the final drug entity, is still alive and well. Thus, in the area of cancer, over the time frame from around the 1940s to date, of the 175 small molecules, 131, or 74.8%, are other than "S" (synthetic), with 85, or 48.6%, actually being either natural products or directly derived therefrom. In other areas, the influence of natural product structures is quite marked, with, as expected from prior information, the anti-infective area being dependent on natural products and their structures. Although combinatorial chemistry techniques have succeeded as methods of optimizing structures and have been used very successfully in the optimization of many recently approved agents, we are able to identify only one de novo combinatorial compound approved as a drug in this 30-year time frame. We wish to draw the attention of readers to the rapidly evolving recognition that a significant number of natural product drugs/leads are actually produced by microbes and/or microbial interactions with the "host from whence it was isolated", and therefore we consider that this area of natural product research should be expanded significantly.

Indexed as

Biological ProductsCombinatorial Chemistry TechniquesDrug ApprovalHistory, 20th CenturyHistory, 21st CenturyMolecular StructurePharmacologyResearchBiological Products

Identifiers

PMID22316239
PMCPMC3721181

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.